3400万美元！相达生物科技斩获亚洲诊断技术领域近六年最大A轮融资

Group 1 - The core viewpoint of the news is that Xiangda Biotechnology has successfully completed a $34 million Series A financing round, marking the largest Series A financing in the Asian diagnostic technology sector since 2019 [1] - The funds raised will be used to accelerate the development of advanced early disease screening technologies and to further commercialize diagnostic solutions for various cancers, women's health, and infectious diseases [1] - The CEO of Xiangda Biotechnology emphasized that investors are now focusing not only on market potential and technological prospects but also on the company's commercialization capabilities [1] Group 2 - Xiangda Biotechnology's proprietary PHASIFY urine concentration technology enhances the sensitivity of biomarker detection by over ten times the gold standard [2] - The company has developed the world's first HPV urine sample test, which has shown a sensitivity of 93.4% for CIN2+ lesions in recent clinical studies [2] - The liquid biopsy market is projected to grow from $7.05 billion in 2025 to approximately $22.69 billion by 2034, driven by the demand for non-invasive cancer diagnostics [2] Group 3 - The HPV urine sample test is a flagship product for Xiangda Biotechnology, providing a non-invasive detection method that aligns with the current trend towards non-invasive testing [3] - The product has received recognition from top scholars in the relevant fields and is expected to be included in the National Essential Medicines Clinical Application Guidelines in the coming years [3] - The company has previously secured $3 million in startup funding from government agencies and $20 million in angel investment, with plans to potentially go public in Hong Kong [3]